<![CDATA[DREAMM-7 Study Design and the Rationale]]>

Regulatoryapprovedbelantamab mafodotinbortezomibdexamethasonePositive

AI Analysis

Summary

Belantamab mafodotin has been approved in combination with bortezomib and dexamethasone for relapsed/refractory multiple myeloma patients with prior PI and IMiD exposure, though the approval carries a boxed warning for ocular adverse effects.

Clinical Trial Data

Outcome Details

Belantamab mafodotin approved in combination with bortezomib and dexamethasone. Boxed warning issued for ocular adverse effects.

Importance:7/10

Sentiment:

0.60

FDA approvalmultiple myelomabelantamab mafodotincombination therapyboxed warningocular toxicity

Related Companies

$PRRUF

Read the original article

Published by Cancer Network on September 29, 2026 12:05 PM

Read Original